Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib + ARSIs in mCRPC
NCT06457919Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tinengotinib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Recommended Phase 2 Dose at 28 days and Objective Response Rate at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
tinengotinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06457919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06457919.